Estudo da ação imunomoduladora de complexos de ciclodextrinas em modelo experimental de esclerose múltipla
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease that causes
neurodegeneration in the central nervous system (CNS), for which conventional
treatments are limited by high cost, adverse effects, and partial efficacy. In this
context, the search for more effective, safe, and accessible alternatives has led to the
investigation of Ursolic Acid (UA) and Rhodium (Rh) compounds. UA possesses
well-established anti-inflammatory and immunomodulatory actions; however, its
unfavorable physicochemical characteristics present a pharmacotechnical challenge.
On the other hand, while Rh complexes with cyclodextrins have previously shown
immunomodulatory effects in vitro and in vivo, their efficacy in MS models remained
unexplored. Therefore, this study aimed to synthesize, characterize, and evaluate the
immunomodulatory effect of a UA complex with poly-beta-cyclodextrin (UA/pβCD)
and an Rh complex with hydroxypropyl-beta-cyclodextrin (Rh/HPβCD) in the
Experimental Autoimmune Encephalomyelitis (EAE) model. The physicochemical
characterization followed a strategic approach: the formation of Rh/HPβCD, building
upon previous work, was confirmed by Fourier-transform infrared spectroscopy
(FTIR) and thermal analysis (TGA/DTA). The novel UA/pβCD complex was subjected
to an in-depth investigation to elucidate its supramolecular behavior, which included,
in addition to FTIR and TGA/DTA, phase solubility studies, dynamic light scattering
(DLS), and zeta potential analysis. The biological evaluation began in vitro with
cytotoxicity (MTT) and nitric oxide (NO) production assays for UA/pβCD, and
subsequently proceeded to the in vivo evaluation of both complexes in the EAE
model using female C57BL/6 mice. The in-depth characterization of UA/pβCD
revealed the formation of an inclusion complex with a 1:1 stoichiometry, resulting in
increased UA solubility and the formation of stable colloidal nanoparticles in an
aqueous medium. In vitro, the UA/pβCD complex reduced NO production in
macrophages, proving more potent than uncomplexed UA and exhibiting no
cytotoxicity at therapeutic concentrations. In vivo, both complexes, as well as their
parent compounds, significantly attenuated the neurological disability score of EAE.
Notably, uncomplexed Rh demonstrated the most rapid and potent action during the
inflammatory peak of the disease. Ex vivo analyses of the CNS revealed a dual,
compartmentalized action: in the brain, the treatments promoted clear
immunomodulation, with a reduction in the pro-inflammatory cytokine IL-12p70 and
inflammatory infiltrate. In contrast, in the spinal cord, they exerted a potent
neuroprotective effect, decreasing demyelination even without reducing the local
inflammatory infiltrate. In conclusion, the UA and Rh complexes attenuate the
severity of EAE through a combined mechanism of central immunomodulation and
direct neuroprotection. Rh emerged as a highly potent therapeutic agent, while the
complexation of UA proved to be a successful pharmacotechnical strategy for both
improving physicochemical properties and maintaining efficacy, thus warranting
continued investigation into the development of new therapies for MS.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

